Contrasting of Vaxart Inc. (VXRT) and Sierra Oncology Inc. (NASDAQ:SRRA)

This is therefore a comparing of the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership in Vaxart Inc. (NASDAQ:VXRT) and Sierra Oncology Inc. (NASDAQ:SRRA). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vaxart Inc. 4.16M 3.33 18.35M -89.00 0.00
Sierra Oncology Inc. N/A 0.00 49.65M -0.63 0.00

Table 1 highlights Vaxart Inc. and Sierra Oncology Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides Vaxart Inc. and Sierra Oncology Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Vaxart Inc. -441.11% 0% 0%
Sierra Oncology Inc. 0.00% -43.8% -40.8%

Risk & Volatility

Vaxart Inc. has a beta of 0.02 and its 98.00% less volatile than S&P 500. Sierra Oncology Inc. has a 1.69 beta and it is 69.00% more volatile than S&P 500.

Liquidity

2.4 and 2.4 are the respective Current Ratio and a Quick Ratio of Vaxart Inc. Its rival Sierra Oncology Inc.’s Current and Quick Ratios are 14.7 and 14.7 respectively. Sierra Oncology Inc. has a better chance of clearing its pay short and long-term debts than Vaxart Inc.

Institutional & Insider Ownership

Roughly 54.6% of Vaxart Inc. shares are owned by institutional investors while 63.4% of Sierra Oncology Inc. are owned by institutional investors. About 4.87% of Vaxart Inc.’s share are owned by insiders. Comparatively, insiders own roughly 0.96% of Sierra Oncology Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Vaxart Inc. -10.39% -3.5% -9.21% -20% -57.47% -55.69%
Sierra Oncology Inc. -6.75% -8.98% -18.28% -52.35% -46.48% -59.25%

For the past year Vaxart Inc.’s stock price has smaller decline than Sierra Oncology Inc.

Summary

Vaxart Inc. beats Sierra Oncology Inc. on 6 of the 9 factors.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.